Charles River Laboratories International, Inc. (CRL)
NYSE: CRL · Real-Time Price · USD
167.64
+5.56 (3.43%)
Nov 21, 2025, 4:00 PM EST - Market closed
CRL Revenue
Charles River Laboratories International had revenue of $1.00B in the quarter ending September 27, 2025, a decrease of -0.49%. This brings the company's revenue in the last twelve months to $4.02B, down -0.92% year-over-year. In the year 2024, Charles River Laboratories International had annual revenue of $4.05B, down -1.92%.
Revenue (ttm)
$4.02B
Revenue Growth
-0.92%
P/S Ratio
2.09
Revenue / Employee
$200,184
Employees
20,100
Market Cap
8.25B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 28, 2024 | 4.05B | -79.42M | -1.92% |
| Dec 30, 2023 | 4.13B | 153.35M | 3.86% |
| Dec 31, 2022 | 3.98B | 435.90M | 12.31% |
| Dec 25, 2021 | 3.54B | 616.23M | 21.08% |
| Dec 26, 2020 | 2.92B | 302.71M | 11.55% |
| Dec 28, 2019 | 2.62B | 355.13M | 15.67% |
| Dec 29, 2018 | 2.27B | 408.50M | 21.99% |
| Dec 30, 2017 | 1.86B | 176.17M | 10.48% |
| Dec 31, 2016 | 1.68B | 318.13M | 23.34% |
| Dec 26, 2015 | 1.36B | 65.64M | 5.06% |
| Dec 27, 2014 | 1.30B | 132.13M | 11.34% |
| Dec 28, 2013 | 1.17B | 36.00M | 3.19% |
| Dec 29, 2012 | 1.13B | -13.12M | -1.15% |
| Dec 31, 2011 | 1.14B | 9.23M | 0.81% |
| Dec 25, 2010 | 1.13B | -38.23M | -3.26% |
| Dec 26, 2009 | 1.17B | -123.66M | -9.55% |
| Dec 27, 2008 | 1.30B | 64.67M | 5.26% |
| Dec 29, 2007 | 1.23B | 172.24M | 16.27% |
| Dec 30, 2006 | 1.06B | 65.06M | 6.55% |
| Dec 31, 2005 | 993.33M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 435.16B |
| Johnson & Johnson | 92.15B |
| Merck & Co. | 64.24B |
| AbbVie | 59.64B |
| Eli Lilly and Company | 59.42B |
| AstraZeneca | 58.13B |
| Novartis AG | 56.37B |
| Novo Nordisk | 49.58B |
CRL News
- 3 days ago - Madison Small Cap Fund Q3 2025 Portfolio Activity - Seeking Alpha
- 5 days ago - Charles River Laboratories International, Inc. (CRL) Presents at Jefferies London Healthcare Conference 2025 Transcript - Seeking Alpha
- 6 days ago - SOLVE and Charles River Development Partner to Deliver Integrated Fixed Income Pricing for Investment Managers - Business Wire
- 7 days ago - Charles River Laboratories to Present at Jefferies Global Healthcare Conference - Business Wire
- 18 days ago - Charles River Laboratories International, Inc. (CRL) Q3 2025 Earnings Call Transcript - Seeking Alpha
- 18 days ago - Charles River Beat Expectations But Why Is The Stock Falling? - Benzinga
- 18 days ago - Charles River: Mixed Q3 As Strategic Review Disappoints - Seeking Alpha
- 19 days ago - Charles River raises annual profit forecast on stabilizing biotech demand - Reuters